Structure’s Oral Weight Loss Drug Data Underperforms A Big Rival

 
• By Jessica Merrill

The company is advancing a Phase II candidate in the closely watched and competitive category of oral GLP-1 receptor agonists for diabetes and weight loss.

tape measure
Investors weren't sure Structure's Phase II data measures up to Lilly's • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas